相关实验视频
Updated: May 24, 2025
13:00
Engineering Antiviral Agents via Surface Plasmon Resonance
Published on: June 14, 2022
2.3K
通过活性部位的氨酸氨酸抑制SARS-CoV-2 NiRAN域的共价抑制
Genaro Hernandez1, Adam Osinski2, Abir Majumdar2
1Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
The Journal of biological chemistry
|March 6, 2025
概括
研究人员开发了一种高通量试验,以找到SARS-CoV-2 NiRAN域的抑制剂. 他们确定了NCI-2,一种向nsp12的共价抑制剂,提供了针对COVID-19的新策略.
科学领域:
- 病毒学 病毒学
- 药物发现 药物发现 药物发现
- 结构生物学 结构生物学
背景情况:
- SARS-CoV-2 nsp12 蛋白质含有 NiRAN 域,该域对于病毒RNA 封闭和复制至关重要.
- 这个NiRAN域代表了针对COVID-19的抗病毒药物开发的潜在目标.
研究的目的:
- 开发一种高通量选试验,用于识别SARS-CoV-2 NiRAN域的小分子抑制剂.
- 描述一种针对NiRAN域的新型共价抑制剂及其作用机制.
主要方法:
- 开发一种用于选NiRAN抑制剂的高通量试验.
- 鉴定和描述NiRAN共价抑制剂2 (NCI-2).
- 低温电子显微镜 (cryo-EM) 用于确定受抑制复合物的结构.
主要成果:
- 发现了一种新型的共价抑制剂,NCI-2,它向NiRAN域的活性位点氨酸 (Cys53).
- NCI-2证明了进入细胞并使nsp12蛋白失活的能力.
- 化EM提供了与NCI-2结合的SARS-CoV-2复制-转录复合物的详细结构模型.
结论:
- 这项研究提出了一个可行的策略,用于开发针对 SARS-CoV-2 的 NiRAN 向抗病毒药物.
- 虽然NCI-2显示细胞功效有限,但结构洞察力为设计更有效的抑制剂铺平了道路.
- 这项研究有助于开发针对COVID-19和未来的冠状病毒威胁的治疗干预措施.
关键词:
在 COVID-19 疫情中,尼兰尼兰是什么意思在RNA封闭过程中,RNA被封闭.这就是SARS-CoV-2病毒.发现药物的发现.药物查对药物进行查.酶抑制剂是一种酶抑制剂.酶结构 酶结构抑制剂抑制剂的使用伪酶是一种假酶.更多相关视频
08:40Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
Published on: March 1, 2019
58.9K
07:53A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation
Published on: January 9, 2019
33.1K
相关概念视频
01:30Enzyme Inhibition
77.7K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
77.7K
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K